Downloads

  1. AI: The Inflection Point In Retinal Drug Discovery, Development, And Delivery 4/21/2026

    AI won’t replace clinical or biological insight; instead pairing AI with scientific expertise will sharpen and accelerate retinal therapeutic development.

  2. A Miniaturized, Semi-Automated RNA-seq Workflow 4/20/2026

    A streamlined RNA‑seq workflow enables high‑throughput gene expression profiling directly from cell lysates, reducing cost and complexity. See how this approach accelerates lead selection.

  3. AI, Digitalization, And In Vivo Programming Redefine Cell And Gene Therapy 4/20/2026

    By merging precision genetic engineering with the scalability of nanomedicine and the predictive power of AI, scientists are reshaping the future of human health.

  4. Antibiotic-Resistant STIs: Men's Health Is Entering A New Era Of Therapeutic Risk 4/20/2026

    What was once a reliably treatable infection is increasingly defined by resistance patterns that limit therapeutic options and complicate management.

  5. If AI Can't Read Your Science, Investors Won't Either 4/17/2026

    As investors deploy AI to screen thousands of deals at once, life sciences founders who keep their story locked behind NDAs risk never making it past the first automated filter.

  6. Master The Art Of Pipetting And Learn How To Perform Serial Dilutions 4/16/2026

    Accurate serial dilutions depend on more than calculations. Learn how mixing, tip handling, and workflow consistency influence accuracy, as well as how small adjustments can improve reproducibility.

  7. U.S. Pharma Tariffs And MFN Become Law After April 2 Update 4/15/2026

    Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them.

  8. ADC Development Grows More Complex — SPR Insights Bring Clarity 4/14/2026

    Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.

  9. There's A Gap In Brain Tumor Research — Here's How We Fix It 4/9/2026

    Brain tumors are some of the most biologically complex and least improved indications. Biochemistry researcher and scientist Catherine Bladen, Ph.D., argues sustained focus is a key to driving real-world progress.

  10. Lessons Learned While Taking Glioblastoma Drug From Bench To Clinic 4/9/2026

    MimiVax CEO Mike Ciesielski recounts the company's transition from academia to industry, hitting on topics like vendor partnerships, FDA conversations, and manufacturer selection.